{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:22Z","timestamp":1761513442372},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[1994,1]]},"DOI":"10.1007\/bf03344963","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T10:20:48Z","timestamp":1396088448000},"page":"51-57","source":"Crossref","is-referenced-by-count":26,"title":["A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients"],"prefix":"10.1007","volume":"17","author":[{"given":"Massimo","family":"Giusti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Porcella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cuttica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,18]]},"reference":[{"key":"BF03344963_CR1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0889-8529(18)30234-2","volume":"21","author":"RE Blackwell","year":"1992","unstructured":"Blackwell R.E. Hyperprolactinemia evaluation and management. Endocrinol. Metab. Clin. 21: 105, 1992.","journal-title":"Endocrinol. Metab. Clin."},{"key":"BF03344963_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.me.40.020189.001301","volume":"40","author":"ME Molitch","year":"1989","unstructured":"Molitch M.E. Management of prolactinomas. Ann. Rev. Med. 40: 225, 1989.","journal-title":"Ann. Rev. Med."},{"key":"BF03344963_CR3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2265.1986.tb03279.x","volume":"24","author":"G Benker","year":"1986","unstructured":"Benker G., Gieshoff B., Freundieb O., Windeck R., Schulte H.M., Lancranjan I., Reinwein D. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours. Clin. Endocrinol (Oxf.) 24: 505, 1986.","journal-title":"Clin. Endocrinol (Oxf.)"},{"key":"BF03344963_CR4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/09513599109028443","volume":"5","author":"D Gianola","year":"1991","unstructured":"Gianola D., Pedroncelli A., Montini M., Tengattini F., Pagani M.C.Cortesi L, Cappi M.P., Gherardi F., Lancranjan I., Pagani G. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients. Gynecol. Endocrinol. 5: 213, 1991.","journal-title":"Gynecol. Endocrinol."},{"key":"BF03344963_CR5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/jcem-72-3-635","volume":"72","author":"SWS Lamberts","year":"1991","unstructured":"Lamberts S.W.S., Quick R.F. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab. 72: 635, 1991.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03344963_CR6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","volume":"69","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 69: 725, 1989.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03344963_CR7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1210\/jcem-68-6-1201","volume":"68","author":"C Ferrari","year":"1989","unstructured":"Ferrari C, Mattei A.M., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 68: 1201, 1989.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03344963_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C., Paracchi A., Mattei A.M., De Vincentis S., D\u2019AIberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126: 489, 1992.","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BF03344963_CR9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.1992.tb01485.x","volume":"37","author":"J Webster","year":"1992","unstructured":"Webster J., Piscitelli G., Polli A., D\u2019AIberton A., Falsetti L., Ferrari C, Fioretti P., Giordano G., L\u2019Hermite M., Ciccarelli E., Crosignani P.G., De Cecco L., Fadini R., Faglia G., Flamigni F., Tamburrano G., Scanion M.F. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin. Endocrinol. (Oxf.) 37: 534, 1992.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03344963_CR10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","volume":"32","author":"R Homburg","year":"1990","unstructured":"Homburg R., West C., Brownell J., Jacobs H.S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205\u2013502, with bromocriptine in women with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 32: 565, 1990.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03344963_CR11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2265.1989.tb01263.x","volume":"31","author":"CB Newman","year":"1989","unstructured":"Newman C.B., Hurley A.M., Kleinberg D.L. Effects of CV 205\u2013502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin. Endocrinol. (Oxf.) 31: 391, 1989.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03344963_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2265.1988.tb01225.x","volume":"29","author":"C Rasmussen","year":"1988","unstructured":"Rasmussen C, Bergh T., Wide L, Brownell J. Long-term treatment with a non-ergot long-acting dopamine agonist CV 205\u2013502, in women with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 29: 271, 1988.","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BF03344963_CR13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1530\/acta.0.1250170","volume":"125","author":"C Rasmussen","year":"1991","unstructured":"Rasmussen C., Brownell J., Bergh T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205\u2013502. Acta Endocrinol. (Copenh.) 125: 170, 1991.","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BF03344963_CR14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1210\/jcem-68-2-336","volume":"66","author":"ML Vance","year":"1989","unstructured":"Vance M.L., Cragun J.R., Reimnitz C., Chang R.J., Rashef E., Blackwell R.E., Miller M.M., Molitch M.E. CV 205\u2013502 treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab. 66: 336, 1989.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03344963_CR15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","volume":"46","author":"PP Heijden Van der","year":"1991","unstructured":"Van der Heijden P.P., De Wit W., Brownell J., Schoemaker J., Rolland R. CV 205\u2013502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur. J. Obstet. Gynecol. Reprod. Biol. 46: 111, 1991.","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"BF03344963_CR16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1530\/acta.0.1250385","volume":"125","author":"JA Verhelst","year":"1991","unstructured":"Verhelst J.A., Froud A.L., Touzel R., Wass J.A.H., Besser G.M., Grossman A.B. Acute and long-term effects of once-daily oral bromocriptine and a new long acting non ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol. (Copenh.) 125: 385, 1991.","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BF03344963_CR17","first-page":"190","volume-title":"Research Reports on Gynecology and Obstetrics","author":"M Giusti","year":"1990","unstructured":"Giusti M., Durante M., Cavagnaro P., Sghedoni D., Giordano G. Two years of experience using cabergoline in the treatment of women with pathological hyperprolactinaemia. In: Genazzani A.R., Petraglia F., Volpe A. (Eds.), Research Reports on Gynecology and Obstetrics. Parthenon Publishing Group, Carnforth, vol. 2, 1990, p. 190."},{"key":"BF03344963_CR18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","volume":"100","author":"ML Vance","year":"1984","unstructured":"Vance M.L., Evans W.S., Thorner M.O. Bromocriptine. Ann. Intern. Med. 100: 78, 1984.","journal-title":"Bromocriptine. Ann. Intern. Med."},{"key":"BF03344963_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF03347152","volume":"10","author":"E Ciccarelli","year":"1987","unstructured":"Ciccarelli E., Mazza E., Ghigo E., Guidoni F., Barberis A., Massara F., Camanni F. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia. J. Endocrinol. Invest. 10: 51, 1987.","journal-title":"J. Endocrinol. Invest."},{"key":"BF03344963_CR20","first-page":"577","volume":"74","author":"T Brue","year":"1992","unstructured":"Brue T., Pellegrini I., Gunz G., Morange I., Dewailly D., Brownell J., Enjalbert A., Jaquet P. Effects of the dopamine agonist CV 205\u2013502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab. 74: 577, 1992.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03344963_CR21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7326\/0003-4819-112-9-668","volume":"112","author":"ML Vance","year":"1990","unstructured":"Vance M.L, Upper M., KIibanski A., Biller B.M.K., Samaan N.A., Molitch M.E. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non ergot dopamine agonist CV 205\u2013502. Ann. Intern. Med. 112: 668, 1990.","journal-title":"Ann. Intern. Med."},{"issue":"Suppl.1","key":"BF03344963_CR22","first-page":"32","volume":"7","author":"E Salle Di","year":"1984","unstructured":"Di Salle E., Ornati G., Giudici D. A comparison of the in vivo and in vitro duration of prolactin lowering effects in rats of FCE 21226, pergolide and bromocriptine. J. Endocrinol. Invest. 7(Suppl. 1): 32, 1984.","journal-title":"J. Endocrinol. Invest."},{"key":"BF03344963_CR23","first-page":"261","volume-title":"Endocrinology","author":"E Fluckiger","year":"1986","unstructured":"Fluckiger E. Pharmacological profile of dopaminergic agents. In: Molinatti G.M., Martini L. (Eds.), Endocrinology. Elsevier Science Publishers, Amsterdam, 1986, p. 261."},{"key":"BF03344963_CR24","first-page":"891","volume":"81","author":"PS Barnett","year":"1991","unstructured":"Barnett P.S., Palazidou E., Miell J.P., Coskeran P.B., Butler J., Dawson J.M., Maccabe J., McGregor A.M. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV 205\u2013502. Quart. J. Med. 81: 891, 1991.","journal-title":"Quart. J. Med."},{"key":"BF03344963_CR25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jcem-71-2-354","volume":"71","author":"Y Khalfallah","year":"1990","unstructured":"Khalfallah Y., Claustrat B., Grochowicki M., Flocard F., Horlait S., Serusclat P., Sassolas G. Effects of a new prolactin inhibitor, CV 205\u2013502, in the treatment of human prolactinomas. J. Clin. Endocrinol. Metab. 71: 354, 1990.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03344963_CR26","first-page":"71","volume-title":"CV 205\u2013502: 1st International Round Table Conference","author":"G Sassolas","year":"1990","unstructured":"Sassolas G., Khalfallah Y., Trouillas J. CV 205\u2013502, new prolactin inhibitor, prevents tumour development and induces tumor reduction in an animal model and in human prolactinoma. In: Besser G.M., Lamberts S.W.J. (Eds.), CV 205\u2013502: 1st International Round Table Conference. Medicom, Europe, 1990, p. 71."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03344963.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03344963\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03344963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T01:58:35Z","timestamp":1565315915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03344963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["BF03344963"],"URL":"https:\/\/doi.org\/10.1007\/bf03344963","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}